In vitro activity of ceftolozane-tazobactam against Enterobacter cloacae complex clinical isolates with different {beta}-lactam resistance phenotypes [PublishAheadOfPrint]

The study evaluated the in vitro activity of ceftolozane-tazobactam (C/T) against 94 unique clinical isolates of Enterobacter cloacae complex (ECC). No difference was observed according to the ECC cluster. The in vitro activity greatly varied depending on the β-lactamase-producing profile: 100%, 67% and 19% of wild-type, ESBL-producing, and AmpC-overproducing strains were susceptible to C/T, respectively. The use of C/T could be of interest for the treatment of some infections caused by ESBL-producing AmpC-non-overexpressing ECC isolates.

https://ift.tt/2ljMkBa